JMP Securities Starts NovoCure Ltd. (NVCR) at Market Outperform
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as FY2027 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Novocure Reports Third Quarter 2015 Operating and Financial Results
October 26, 2015 4:05 PM EDTFDA approved Optune in combination with temozolomide for the treatment of newly diagnosed glioblastoma on October 5, 2015
CE Mark was placed on the second generation Optune system. First patients treated in Europe with the newly designed, smaller, lighter system
468 active patients at quarter end, an increase of 161% versus the prior year quarter end
ST. HELIER, Jersey--(BUSINESS WIRE)-- Novocure (NASDAQ: NVCR), a commercial stage oncology company pioneering a novel therapy for solid tumors, today reported operating and financial results for the three and nine months ended September 30, 2015.
... More
